MANHATTAN PHARMACEUTICALS PRESENTS PRELIMINARY OBESITY DRUG DATA

Manhattan Pharmaceuticals recently presented preliminary Phase I results of its obesity drug candidate, Oleoyl-estrone (OE), an experimental, orally administered small molecule in development for the treatment of obesity, at the 2005 Annual Scientific Meeting of NAASO, the Obesity Society, in Vancouver, British Columbia.

The first of the studies, a Phase Ia, was a dose-escalating study to measure OE's pharmacokinetic profile, safety and tolerability in 36 obese males and females. Twelve of the 36 patients received placebo and 24 received a single dose of OE in one of six strengths ranging from 1 mg to 150 mg.

The second study, a Phase Ib, measured the drug's safety and tolerability in 24 obese volunteers in four cohorts of six patients each receiving either placebo or OE in doses ranging from 10 mg to 150 mg for seven consecutive days.